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Abstract Treatment with rhBMP7 exerts profound protective
effects in a wide variety of experimental models of renal dis-
ease. However, little is known about how these protective
effects are mediated, and which cells in the kidney are targeted
by exogenous rhBMP7 treatment. To determine if rhBMP7
increases glomerular and tubulointerstitial canonical BMP
signaling, we performed Unilateral Ureteral Obstruction
(UUO, a widely used obstructive nephropathy model) in mice
reporting transcriptional activity downstream of canonical
BMP signaling by the expression of GFP under the BMP
Responsive Element of the Id1 promoter (BRE:gfp mice).
We also analysed the impact of rhBMP7 treatment on severity
of the UUO phenotype, on TGFβ signaling, and on expres-
sion of CCN2 (CTGF). Despite profound protective effects
with respect to morphological damage, macrophage in-
filtration, and fibrosis, no significant difference in GFP-
expression was observed upon rhBMP7 administration.
Also TGFβ signalling was similar in rhBMP7 and ve-
hicle treated mice, but CCN2 expression in obstructed
kidneys was significantly reduced by rhBMP7 treatment. Of
note, in heterozygous CCN2 mice (CCN2+/−) treatment with
rhBMP7 did not (further) reduce the severity of kidney dam-
age in the UUO-model. These data suggest that protection
against obstructive nephropathy by exogenous rhBMP7 treat-
ment relies primarily on non-canonical BMP signaling,
and may be mediated in large part by downregulation of
CCN2 expression.
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Abbreviations
BMP7 Bone Morphogenetic Protein 7
CCN2 Cyr61-CTGF-Nov family protein 2
CTGF Connective Tissue Growth Factor
CKD Chronic Kidney Disease
UUO Unilateral Ureteral Obstruction
BW Body Weight
OBK Obstructed Kidney
CLK Contralateral Kidney
GFP Green Fluorescent Protein
TGFβ Transforming Growth Factor β
LTA Lotus tetragonolobus Agglutinin
Introduction
Irrespective of underlying aetiology, chronic kidney disease
(CKD) involves structural changes, and ultimately loss of
function and fibrosis. Although, there is no effective treat-
ment, several potential targets for intervention in CKD pro-
gression have been identified. Transforming Growth Factor
beta (TGFβ) is generally regarded as the main culprit driving
CKD progression (Meng et al. 2015). Numerous studies
targeting TGFβ in various experimental diseases have yielded
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favourable results, but recent clinical trials have questioned
efficacy of available interventions in human CKD (Akhurst
and Hata 2012; Muñoz-Félix et al. 2015) (Clinicaltrial.gov
numbers NCT00464321 and NCT01113801).
The administration of recombinant human BMP7
(rhBMP7; Bone Morphogenetic Protein 7) has been proposed
as an attractive alternative intervention to stop progression of
CKD. Several landmark papers have shown efficacy of BMP7
treatment in a wide range of experimental models of renal
disease including diabetic nephropathy, obstructive uropathy,
nephron loss and ischemic injury (Vukicevic et al. 1998;
Hruska et al. 2000; Morrissey et al. 2002; Wang et al. 2003;
Zeisberg et al. 2003; Dube et al. 2004; Sugimoto et al. 2007),
and a BMP-mimetic (THR-185) is under study in a phase II
clinical trial (Clinicaltrial.gov number NCT01830920).
BMP7 treatment is considered to attenuate experimental
CKD at least in part by antagonizing TGFβ (Wang and
Hirschberg 2003; Zeisberg et al. 2003). BMP7 is required
for kidney development and remains highly expressed during
adult life (Dudley et al. 1995). Although also several other
BMPs are expressed in the kidney throughout development
and adulthood, including BMP4 and BMP6, the potential ther-
apeutic effects of BMP7 are considered most potent (Zeisberg
et al. 2003; Dendooven et al. 2011).
Despite all evidence supporting BMP7 efficacy in CKD,
the identity and localization of cells responding to exogenous
BMP7 treatment remain to be identified. Previous studies in
BMP canonical signaling reporter mice (BRE:gfp mice) iden-
tified glomerular and collecting duct cells to have high endog-
enous BMP signalling activity (Leeuwis et al. 2011).
Signaling activity in the glomeruli and medulla dropped upon
Unilateral Ureteral Obstruction (UUO), but it increased in the
proximal tubular compartment. However, if and to what extent
exogenous BMP7 therapeutic efficacy might involve restora-
tion of canonical signaling activity in these particular cells or
other nephron segments or cell types is still unclear.
CCN2, also known as Connective Tissue Growth Factor
(CTGF) is yet another factor involved in CKD progression
(Falke et al. 2014). CCN2 contributes to fibrosis bymodulating
signaling activity in BMP7, TGFβ, and other signaling path-
ways (Abreu et al. 2002; Nguyen et al. 2008). CCN2 expres-
sion is increased in essentially all progressive kidney diseases,
and CCN2 inhibition decreases loss of function and fibrosis
(Ito et al. 1998; Falke et al. 2014; Ren et al. 2015). CCN2
can bind to BMP7 thereby inhibiting canonical SMAD1/5/8
signalling, and as such might also be an important determinant
of the efficacy of BMP7 treatment (Nguyen et al. 2008).
In this study, we set out to shed more light on the mode of
action of exogenous BMP7 therapy by analysing distribution
of transcriptional activity downstream of canonical BMP sig-
naling, and the associated complex interplay between BMP7,
TGFβ, and CCN2 in rhBMP7 treated BRE-GFP reporter mice
subjected to UUO.
Materials and methods
Animals
Generation of bone morphogenetic protein responsive ele-
ment (BRE); Green Fluorescent Protein (GFP) reporter mice
has been described in detail elsewhere (Monteiro et al. 2008).
Briefly, these mice express GFP under control of the BRE in
the Id1 gene promoter, thus reporting transcriptional activity
downstream canonical BMP signaling. Male BRE:gfp mice
on a C57Bl6/J background were used for this study. CCN2
hemizygous KO mice were used to estimate the relative con-
tribution of CCN2 reduction to the therapeutic effect of exog-
enous BMP7. CCN2 (hemizygous) KO mice have been de-
scribed previously (Ivkovic et al. 2003). Mice were kept on a
12-h light/day cycle with food and water ad libitum. All work
was carried out with approval of the Experimental Animal
Ethics Committee of the University of Utrecht.
Unilateral ureteral obstruction/BMP7 administration
Mice were subjected to Unilateral Ureteral Obstruction under
general isoflurane anaesthesia. The left flank was incised and
the ureter was exposed and tied off using silk sutures. Directly
after ligation, a depot of 300 μg/kg rhBMP7 (dissolved in
PBS; kindly provided by Stryker, Kalamazoo, MI) per mouse
was left intraperitoneally (i.p.). The wound was closed
using 5–0 vicryl sutures (Ethicon, Sommerville, NJ).
Mice received an additional 300 μg/kg rhBMP7 i.p.
on day 2, 4 and 6 (n = 9). Vehicle (PBS) injected mice
were used as control (n = 6). 3 mice were used for
CCN2 hemizygous groups. At day 7 mice were killed
by ketamin, xylazine and acepromazine overdose. Kidney tis-
sue was fixed in fresh 4 % paraformaldehyde solution and
embedded in paraffin, or snap frozen and stored at −80 °C
until further processing.
(Immuno)histochemistry
Sections (3 μm) were cut from paraffin blocks, deparaffinised
and rehydrated. For assessment of morphological changes,
sections were stained with Periodic Acid Schiff using standard
methods. 10 random cortical fields of PAS stained sections
were scored on a five-point scale for tubular atrophy or dila-
tation (0 = 0–10 %, 1 = 10–25 %, 2 = 25–50 %, 3 = 50–75 %,
4 = 75–100 %). Masson Tri Chrome (MTC) and Sirius Red
staining was performed using standardized protocols at the
clinical diagnostics laboratory of our department.
Direct fluorescence of 20 glomeruli per kidney was
assessed in images acquired by confocal laser scanning mi-
croscopy (CLSM), followed by ImageJ analysis of signal in-
tensity. Likewise, direct tubuloinsterstitial GFP signal was
assessed in CLSM images by analyzing area positivity and
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single channel pixel intensity of 10 cortical fields from which
glomeruli were deselected.
For immunohistochemistry, slides were boiled in EDTA or
citrate buffer for antigen retrieval where appropriate, and in-
cubated with the following antibodies: anti-GFP (Ab290 ,
rabbit polyclonal, Citrate, 1:1000, Abcam, Cambridge, UK),
HRP-linked LTA (Citrate, 1:32, Sigma-Aldrich, St. Louis,
MO), anti-CCN2 (L20 , goat polyclonal, Citrate, 1:200,
Santa-Cruz Biotechnology, Santa Cruz, CA), anti-F4/80
(Fresh Frozen tissue, rat monoclonal, 1:3000, Serotec/Biorad
antibodies, Oxford, UK) or anti-αSMA (Ab5694, rabbit poly-
clonal, EDTA, 1:200, Abcam). Ready to use Horse Radish
Peroxidase (HRP) linked BrightVision (ImmunoLogic,
Duiven, NL) species specific secondary antibody solution,
followed by NovaRed (Vector laboratories, Burlingham,
CA) or 3,3′-diaminobenzidine (Sigma Aldrich, St. Louis,
MO) were applied for chromogen color development to visu-
alize bound primary antibody.
The number of proximal tubule cross sections per cortical
surface area was counted in 10 random fields per kidney
(200× magnified). Using Photoshop (Adobe, San Jose, CA),
a colour selection of positively stained area was made
after which pictures were dichotomized in IHC positive
and staining negative pixels. Using this method, the
percentage positive cross sectional surface area for GFP, F4/
80, and αSMA respectively, was determined in 10 cortical
fields photographed at 200× magnification by ImageJ
analysis (NIH).
For glomerular GFP IHC area positivity, pictures of 20
glomeruli per kidney were converted into binary images.
Supplemental Fig. 1 A shows one example of a binary image
of the CLK from the vehicle group illustrating what is
regarded as total and positive area for calculation of positive
area percentage. The red dotted lines define the circumference
of two glomeruli. The enclosed total glomerular cross-
sectional surface is used for calculation of glomerular positive
area percentage. The total glomerular cross-sectional surface
area is excluded for calculation of tubulointerstitial positive
area percentage.
RT-qPCR
Full Kidney cortex mRNA was isolated using Trizol and
3000 ng of mRNAwas reversely transcribed into cDNA. RT-
qPCR was performed on a LightCycler480 (Roche, Basel,
Switzerland), using commercially available TaqMan primer
assays (Thermo Fisher/Life technologies, Waltham, MA):
(Yhwaz; Mm03950126_s1, Ctgf, Mm00515790_g1; Tgfβ1,
Mm01178820_m1; Col1α2, Mm00483888_m1; Pai1,
Mm00435860_m1). Sybr green GFP primers and probe were
designed with Primer Express (Applied Biosystems, Foster
City, CA) and purchased from Eurogentec (Maastricht,
The Netherlands) (primers) and Applied Biosystems (probe).
Yhwaz expression was used as internal reference. Relative ex-
pression values were calculated using the ΔΔCT method.
Statistics
All statistical analyses were performed using Graphpad Prism
(GraphPad, LaJolla, CA). ANOVAwith Tukey post-hoc cor-
rection for multiple testing or Student T-test were used where
appropriate. A p-value below 0.05 was considered statistically
significant.
Results
Exogenous BMP7 does not increase BRE:gfp reporter
signal for transcriptional activity downstream
of canonical BMP7 signaling
Body weight, kidneys weights and kidney weight/body
weight ratios of rhBMP7 treated BRE:gfp mice were not sig-
nificantly different from those in vehicle treated mice (See
Table 1). BRE:gfp mice express GFP under a SMAD binding
element in the Id1 promotor region and thereby report tran-
scriptional activity downstream of canonical BMP signaling
(Korchynskyi and Dijke ten 2002; Monteiro et al. 2008).
Glomerular GFP intensity tended to be slightly lower in
Table 1 Body and kidney
weights of both treatment groups.
Average (+/− standard deviation)
is shown
Vehicle (n = 6) rhBMP7 (n = 9) p-value
BW start (g) 25.92 (+/−4.41) 25.88 (+/− 4.32) 0.99
BWend (g) 25.87 (+/− 3.82) 24.84 (+/− 3.52) 0.61
BWend/BW start 1 (+/− 0.05) 0.96 (+/−0.04) 0.15
CLKW (mg) 211.6 (+/−48.2) 211 (+/− 47.69) 0.98
OBKW (mg) 194.67 (+/− 37.33) 199.88 (+/− 25.98) 0.76
CLKW (mg/g BWs) 8.12 (+/− 0.8) 8.1 (+/− 0.67) 0.96
OBKW (mg/g BWs) 7.52 (+/− 0.9) 7.81 (+/−0.96) 0.58
OBKW/CLKW (mg/mg) 0.91 (+/− 0.08) 0.97 (+/− 0.14) 0.41
Body and kidney weights of both treatment groups. Average (+/− standard deviation) is shown.
BW body weight, CLKW contralateral kidney weight, OBKW obstructed kidney weight
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obstructed kidneys of vehicle treated mice (P = 0.3; Fig. 1a,
b). Also, in the tubulointerstitial compartment of the kidney
cortex there was a trend towards reduction of GFP-positive
surface area, and GFP signal intensity was slightly reduced
upon obstruction (Suppl. Figure 1a–c). Remarkably, rhBMP7
treatment induced only very limited, non-significant increase
of glomerular GFP fluorescence and altered neither total GFP
positive surface area nor fluorescent signal intensity in GFP
positive tubulointerstitial areas (Fig. 1a, b, Suppl. Figure 1a–c
respectively).
Comparison between GFP signal detected by direct fluo-
rescence and immunohistochemically (IHC) revealed that
IHC detection is more sensitive (Suppl. Figure 2). Using mor-
phometric analysis, percentage positive area of total cortical
sections, tubulointerstitial (TI) compartment and glomeruli
was analysed in sections where GFP was detected by
ImageJ, thus allowing assessment whether canonical BMP
signaling increases in cortical areas where normally signalling
is absent or below detection limit (Suppl. Figure 3).
Average total and TI GFP positive area tended to be lower in
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Fig. 1 rhBMP7 treated BRE:Gfp OBKs do not show increased GFP
expression. a Representative CLSM micrographs of direct glomerular
GFP expression (pseudo colorized). b Quantification of GFP intensity.
C. Representative images of GFP immunohistochemistry in CLKs and
OBKs 7 days after UUO of both vehicle and BMP7 groups (200×
magnified). d-f. Quantification of total area (B), tubules and interstitium
(C) or percentage of the glomeruli (D) positive for GFP. G. Cortical Gfp
mRNA expression. Error bars represent SEM
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OBKs than in CLKs, but the observed difference was not
significant (Fig. 1d, e). Remarkably, also the apparently small
increase of total cortical GFP positive area in rhBMP7 treated
OBKs was not statistically significant (Fig. 1d; p = 0.06), and
totally lost when tubules and glomeruli were analysed sepa-
rately (Fig. 1e, f). Analysis of cortical Gfp mRNA expression
revealed a significant decrease upon ureteral obstruction, but
also here no effect of BMP7 treatment was observed (Fig. 1g).
BMP7 protects against kidney damage and reduces
macrophage infiltration 7 days post-UUO
In PAS stained kidney sections the increase of tubular atrophy
and dilatation in OBKs was attenuated in BMP7-treated mice
(p < 0.005; Fig. 2a, b). Lotus tetragonolobus Agglutinin
(LTA) staining revealed that the number of LTA+ proximal
tubules was decreased in OBKs compared to CLKs, but less
so in BMP7 treated mice (Fig. 2c, d; p < 0.01) Additionally,
the OBK/CLK ratio was significantly higher in rhBMP7 treat-
ed animals (p < 0.05).
Macrophage infiltration in OBKs, as assessed by F4/80
IHC, was markedly reduced in the BMP7 treated group
(p < 0.005; Fig. 2e, f).
Fibrogenesis is reduced in BMP7 treated OBKs
After 7 days of obstruction, the OBKs of vehicle treated mice
showed only a little increase in fibrosis (Suppl. Figure 4).
Accumulation of myofibroblasts in OBKS, as assessed by
αSMA positive surface area, was decreased by BMP7
Fig. 2 rhBMP7 treatment
conserves renal morphology and
limits macrophage accumulation
7 days after obstructive
nephropathy. a Representative
images of PAS stained cortical
sections in CLKs and OBKs
7 days after UUO of both vehicle
and BMP7 treated groups (200×
magnified). b Composite of
atrophy and dilatation score
quantified on PAS stained slides c
Representative images of LTA
stained cortical sections in CLKs
and OBKs of both vehicle and
BMP7 treated groups (200×
magnified). d Quantification of
the average number of LTA+
proximal tubules per HPF in
CLKs and OBKs of vehicle and
rhBMP7 treated kidneys. e
Representative images of F4/80
stained cortical sections in CLKs
and OBKs of both vehicle and
BMP7 treated groups (200×
magnified). f Positive area
quantification of F4/80 positive
macrophages in CLKs and OBKs
of vehicle and rhBMP7 treated
kidneys. *p < 0.05, ***p < 0.005.
Error bar represents SEM. Vehicle
n = 6, rhBMP7 n = 9
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treatment (p < 0.005; Fig. 3a, b). Furthermore, the increase of
mRNA for α-sma and Col1α2 was reduced by BMP7 treat-
ment (p < 0.01 and p < 0.005 resp.; Fig. 3c, d).
BMP7 treatment reduced CCN2 expression
but did not alter Tgfβ1expression and transcriptional
activity
Both Tgfβ1 and its canonical transcriptional target Pai-1/
SerpinE1 were upregulated in OBKs (p < 0.005 and
p < 0.01 resp.; Fig. 4a, b), which was not affected by BMP7
treatment. However, BMP7 blocked the increase of CCN2
expression in OBKs (p < 0.05; Fig. 4c, d).
In CCN2 hemizygous KO mice, BMP7 treatment
did not further reduce damage, macrophage infiltration,
and fibrosis of obstructed kidneys
In good agreement with previous reports, we observed less se-
vere kidney damage, macrophage infiltration, and fibrosis in
7 day OBKs of CCN2 hemizygous KO, than in those of wild
type mice. (Suppl. Figure 5a–e). In order to investigate
BMP7 induced reno-protection beyond CCN2 reduction, we
also treated CCN2+/− UUO mice with rhBMP7. The approxi-
mately 50 % reduction of CCN2 expression in CTGF+/− mice
was not further reduced by rhBMP7 treatment (Fig. 5a). In
association with this finding, administration of BMP7 to
CCN2 hemizygous KO mice also failed to further attenuate
renal damage, macrophage infiltration or myofibroblast accu-
mulation (Fig. 5b–d), which emphasizes the importance of
CCN2 reduction in mediating the protective effect of BMP7
treatment in this model of obstructive nephropathy.
Discussion
The present study confirms that rhBMP7 treatment reduces
the severity of kidney damage, macrophage infiltration, and
myofibroblast accumulation in a mouse model of obstructive
nephropathy (UUO). Seven days after UUO, little to no man-
ifest fibrosis was present (Suppl. Figure 3), which might reflect
the relative resistance of C57Bl6 mice to renal fibrosis in
general (Walkin et al. 2013). However, analysis of Col1α2
transcription revealed that de-novo collagen type 1 production
was reduced in rhBMP7 treated mice. Remarkably, transcrip-
tional activity downstream of canonical BMP signaling, and
Fig. 3 rhBMP7 treatment
reduces myofibroblast
accumulation and associated de
novo collagen production. a
Representative images of αSMA
in CLKs and OBKs 7 days after
UUO of both vehicle and BMP7
treated groups (200× magnified).
b Positive area quantification of
αSMA positive myofibroblasts in
CLKs and OBKs of vehicle and
rhBMP7. c and d αSma mRNA
(C) and Col1α2 (D) expression
levels in kidney cortex of CLKs
and OBKs 7 days after UUO of
vehicle and rhBMP7 treated
animals. *p < 0.05, **p < 0.01,
***p < 0.005. Error bars
represent SEM
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also TGFβ expression and transcriptional activity, appeared
not to be altered by rhBMP7 treatment, while the expression
of CCN2 was significantly reduced in the obstructed kidneys
(OBK) of BMP7-treated mice.
In line with previous observations in the BRE-GFP reporter
mouse also used here, the GFP signal was slightly reduced in
distal tubuli of obstructed kidneys (Fig. 1), but we detected no
increase of GFP signal upon rhBMP7-treatment (Manson et al.
2015). Moreover, direct fluorescence of glomeruli and
tubulointerstitium showed that established canonical BMP sig-
nalling was not increased in intensity nor in terms of positive
surface area (Fig. 1a, b, Suppl. Figure 2a–d respectively). Also
with more sensitive immunohistochemical detection of GFP
protein detection, there was no increase of GFP positive area
percentage, indicating that BMP7 did not induce de novo ca-
nonical BMP transcriptional activity in previously negative
cells (Fig. 1c–f). Unfortunately given its non-stoichiometric
nature, IHC signal intensity analysis was not feasible.
However, the lack of increase of transcriptional activity down-
stream of canonical BMP signaling was further underlined by
equal GFPmRNA expression levels in renal cortex of rhBMP7
treated and untreated mice (Fig. 1g). It thus appears that the
protective effects of rhBMP7 treatment in the 7 days UUO
model does not require or involve an increase of canonical
BMP transcriptional activity. This suggests that the beneficial
effects of BMP7 treatment mainly involve non-canonical sig-
naling, rather than transcriptional activity downstream of ca-
nonical BMP signaling. However, since no data are available
on pharmacokinetics of i.p. injected rhBMP7, we cannot fully
exclude that rapid elimination or degradation of de novo
synthesized GFP protein within the 24 h window between the
last BMP7 dose and sacrifice might have Bquenched^ the
reporter signal.
Previously, we have shown that BMP7 treatment of renal
interstitial fibroblasts reduces CCN2 and PAI-1 expression
(Nguyen et al. 2006), and Wang et al. demonstrated that
BMP7 treatment of mesangial cells reduces CCN2,
Fibronectin and Collagen type 4 expression (Wang and
Hirschberg 2003). BMP7 also exerts protective effects on
TGF- β stimulated podocytes (Mitu et al. 2007). As for prox-
imal tubular epithelial cells, Zeisberg et al. showed that BMP7
can inhibit and even reverse TGFβ driven epithelial to mesen-
chymal transdifferentiation, although this could not be con-
firmed by Dudas et al. (Zeisberg et al. 2003; Dudas et al.
2009). In aggregate, it thus appears that rhBMP7 can reduce
(TGFβ-induced) CCN2 expression and associated fibrotic
changes in most cell types of the kidney. However, most evi-
dence for this derives from in vitro cultures only, and the
Fig. 4 rhBMP7 treatment
reduces CCN2 expression levels
without altering canonical TGFβ
signaling. a-c Cortical mRNA
expression levels of Tgfβ1 (A),
Pai-1 (B) and CCN2 (C) in CLKs
and OBKs 7 days after UUO of
vehicle and rhBMP7 treated
CCN2+/− mice. d Representative
images of CCN2
immunohistochemistry in CLKs
and OBKs of both vehicle and
rhBMP7 treated groups (200×
magnified). *p < 0.05, **p < 0.01,
***p < 0.005. Error bars
represent SEM
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relative contribution of canonical as compared to non-
canonical signaling in this has not yet been clearly delineated.
The renoprotective effects of rhBMP7 were associated with
approximately 50 % reduction of CCN2 expression, whereas
expression ofTgfβ1 and its prototypic canonical transcriptional
target Pai-1 remained unaltered (Fig. 4). Efficacy of BMP7
therapy without altering TGFβ signaling has been reported
previously in a model of diabetic nephropathy (Wang et al.
2006). Of note, hemizygous CCN2 deletion (with 50 % re-
duced CCN2 expression), appeared equally effective as
rhBMP7 treatment, with similar reduction of morphological
damage, macrophage infiltration, and collagen and α-SMA
expression (Suppl. Figure 5). This is consistent with previous
observations that an approximately 50 % reduction of
CCN2 expression by genetic deletion or siRNAwas sufficient
to significantly attenuate models of diabetic nephropathy and
obstructive nephropathy (Yokoi et al. 2004; Guha et al. 2007;
Nguyen et al. 2008). With respect to possible concerns
regarding potential a confounding effect of CCN2-
suppression prior- and unrelated to the induction of obstructive
nephropathy, the reduced CCN2 expression in conventional
CCN2+/−mice, did not lead to any renal abnormalities during
development or adult life, and neither did a 90 % CCN2 re-
duction sustained for several weeks (Ivkovic et al. 2003; Falke
et al. 2012; Falke et al. 2014).
Interestingly, administration of rhBMP7 to heterozygous
CCN2 mice tended to even further reduce CCN2 expression,
but this was not associated with a further decrease in damage
and fibrosis. It thus appears that the observed therapeutic ef-
fects might relate to a threshold effect of CCN2 reduction
rather than on a continuous dose-response relation (Fig. 5).
In summary, in the mouse UUO model of obstructive ne-
phropathy we observed efficacy of rhBMP therapy in the ab-
sence of clear evidence for modulation of transcriptional ac-
tivity downstream of canonical BMP signaling. As a conse-
quence, the BRE-GFP reporter mice failed to reveal the
Fig. 5 Treatment with rhBMP7 offers no additional renoprotection in
CCN2+/− heterozygous KO mice. a Average cortical mRNA expression
levels of CCN2 in CLKs and OBKs 7 days after UUO of vehicle and
rhBMP7 treated mice. b-e. Representative micrographs (200× magnified)
and corresponding quantification ofmorphological composite damage score
(B), LTA positive proximal tubules (C), F4/80 positive macrophages (D)
and αSMA positive myofibroblasts (E), in OBKs 7 days after UUO of
vehicle and rhBMP7 treated CCN2+/− mice. *p < 0.05. Error bars
represent SEM
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identity of specific phenotypes and localization of cells
responding to exogenous BMP7 therapy. Furthermore, effica-
cy of BMP7 treatment appeared not to require reduction of
TGFβ expression or transcriptional activity, but was associat-
ed with a reduction of CCN2 expression. Hemizygous dele-
tion of CCN2 was able to reduce UUO severity and BMP7
had no additional effect. Together, these data suggest that pro-
tection against obstructive nephropathy by exogenous BMP7
treatment relates primarily to non-canonical BMP signalling.
Possibly, BMP7 effects are mediated by downregulation of
CCN2 expression.
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